Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Formulations of HRS-1893 Tablets
NCT07479641Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of HRS-1893 in cardiomyopathy (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Peak concentration, Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point and 1 more. Started Apr 2026; status: completed.
02
Drugs
HRS-1893
03
Conditions
cardiomyopathy
Beyond the preview
Go deeper on NCT07479641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479641.